Skip to content
Close-up of a stainless steel AT-Port™ connection with a white tube attached, showing "START" and "STOP" markings - by SKAN.

Where contamination control begins

Safe aseptic manufacturing depends on transfer strategies that minimize contamination risk while ensuring compliance and reproducibility.

Learn more

Why aseptic fluid transfer matters

In sterile pharmaceutical and biotechnology manufacturing, every fluid transfer is a critical control point. A poorly designed transfer step can introduce microbial, particulate, or chemical contamination, create validation gaps, and put product quality, patient safety, and regulatory compliance at risk.

SKAN helps customers reduce that risk by integrating closed transfer technologies, isolator environments, single-use assemblies, automation, and digital monitoring into robust aseptic transfer strategies. The result is a controlled, reproducible, and inspection-ready process from development through commercial GMP manufacturing.

Applications

Fluid transfer across the value chain

  • Cell and gene therapies pictogram.

    Cell and gene therapy

    Secure transfer of viral vectors, plasmid DNA, cell suspensions, and ATMP intermediates.

  • Biopharmaceutical manufacturing

    Controlled handling of bulk drug substances, buffers, media, and process intermediates.

  • Aseptic fill and finish

    Reliable connections for vial, syringe, cartridge, and ready-to-use container closure formats.

  • Toxic or high-potency products

    Transfer strategies that combine product protection with operator and environmental containment.

A stainless steel AT-Port™ on an industrial panel with a mechanical locking lever assembly positioned nearby.
Key transfer challenges

The critical risks behind every transfer

  • Contamination exposure

    Manual operations, open connections, and repeated interventions increase the probability of microbial or particulate ingress.

  • Regulatory scrutiny

    EU GMP Annex 1 and FDA aseptic processing expectations require documented, validated, and risk-based contamination control across the process.

  • Complex product profiles

    Biologics, ATMPs, viral vectors, and high-potency compounds require transfer routes that protect both the product and the operator.

  • Scale-up pressure

    Transfer methods must remain consistent, qualified, and practical as processes move from clinical development to commercial production.

Integrated transfer approach

  • Closed system transfers

    Maintaining a closed fluid pathway is one of the most effective ways to reduce contamination risk during aseptic processing. The AT-Port System and validated aseptic connectors enable secure product transfers while minimizing operator intervention and environmental exposure.

  • Isolator-based protection

    Transfer operations can be integrated within Grade A isolator environments. These controlled barrier systems protect exposed sterile products from the surrounding environment while also safeguarding operators when handling potent or sensitive compounds.

  • Single-use readiness

    Pre-sterilized, application-specific single-use assemblies simplify implementation and help reduce operational complexity. By eliminating cleaning requirements and reducing validation efforts, they support faster setup, improved flexibility, and more efficient changeovers.

  • Automation and traceability

    Integrated monitoring, in-process controls, and digital connectivity provide greater visibility throughout the transfer process, improve compliance, strengthen batch-to-batch consistency, and increase confidence in manufacturing performance.

A gloved hand inserting a white aseptic transfer nozzle into a stainless steel port with locking latches.

Conclusion

Operational and compliance benefits

An effective aseptic fluid transfer strategy delivers benefits that extend beyond contamination control. Closed and validated transfer pathways help increase sterility assurance, while standardized interfaces and well-documented designs support faster validation and qualification activities.

The approach also provides the flexibility needed to support processes from laboratory development through clinical and commercial GMP manufacturing. By reducing manual interventions and simplifying workflows, manufacturers can improve reproducibility, shorten turnaround times, and achieve greater operational efficiency.

From concept to validated transfer strategy

SKAN combines closed transfer technologies, barrier systems, single-use assemblies, and digital process controls into a single, integrated contamination control strategy.

With over 50 years of aseptic processing experience, SKAN supports customers from early concept definition to validated implementation. Our teams help define transfer requirements, select appropriate technologies, integrate them into isolator and process designs, and build the documentation needed for compliant, inspection-ready operations.

By combining technical integration, risk-based design, and practical GMP execution, SKAN enables manufacturers to industrialize aseptic fluid transfer with confidence.

Solutions for fluid transfer

You have questions?

Reach out to our expert team for aseptic fluid transfers.

Back to top